Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Fusion Pharmaceuticals (FUSN)
NASDAQ:FUSN
Fusion Pharmaceuticals (FUSN) Stock Price & Analysis
361 Followers
FUSN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.31 - $21.58
Previous Close$21.48
Volume383.84K
Average Volume (3M)2.01M
Market Cap
$1.83B
Enterprise Value$1.68B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)-15.2
Beta0.76
Next Earnings
Aug 06, 2024EPS Estimate
-$0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.42
Shares Outstanding84,692,585
10 Day Avg. Volume466,291
30 Day Avg. Volume2,007,570
Standard Deviation0.29
R-Squared0.01
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)8.14
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-25.20
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$20.94Price Target Upside-2.51% Downside
Rating ConsensusHold
Number of Analyst Covering14
Fusion Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsPhase II TATCIST data for FPI-2265 shows strong treatment effectiveness, with a 50% PSA50 rate among a subset of patients, indicating a promising outlook for the drug's efficacy.
Market ExpansionFusion Pharmaceuticals plans to initiate a pivotal study for FPI-2265, a next-generation therapy with the potential to significantly impact the market, backed by AstraZeneca's acquisition and resources.
Strategic AcquisitionsAstraZeneca's strategic acquisition of Fusion Pharmaceuticals at a 97% premium highlights the significant value and potential of Fusion's radiopharmaceutical development platform and its lead program FPI-2265.
Bears Say
Analyst SentimentDowngrading to Hold from Buy given announced acquisition.
Clinical Trial OutcomesPotential for significant negative pressure on the stock if the readout is less favorable than hoped.
Market CompetitionThe prostate cancer competitive landscape is crowded
---
Options Prices
Currently, No data available
---
Ownership Overview
28.13% Insiders
10.29% Mutual Funds
7.67% Other Institutional Investors
53.91% Public Companies and
Individual Investors
FUSN FAQ
What was Fusion Pharmaceuticals’s price range in the past 12 months?
Fusion Pharmaceuticals lowest stock price was $2.31 and its highest was $21.58 in the past 12 months.
What is Fusion Pharmaceuticals’s market cap?
Currently, no data Available
When is Fusion Pharmaceuticals’s upcoming earnings report date?
Fusion Pharmaceuticals’s upcoming earnings report date is Aug 06, 2024 which is in 87 days.
How were Fusion Pharmaceuticals’s earnings last quarter?
Fusion Pharmaceuticals released its earnings results on May 07, 2024. The company reported -$0.4 earnings per share for the quarter, missing the consensus estimate of -$0.371 by -$0.029.
Is Fusion Pharmaceuticals overvalued?
According to Wall Street analysts Fusion Pharmaceuticals’s price is currently Overvalued.
Does Fusion Pharmaceuticals pay dividends?
Fusion Pharmaceuticals does not currently pay dividends.
What is Fusion Pharmaceuticals’s EPS estimate?
Fusion Pharmaceuticals’s EPS estimate is -$0.35.
How many shares outstanding does Fusion Pharmaceuticals have?
Fusion Pharmaceuticals has 85,059,970 shares outstanding.
What happened to Fusion Pharmaceuticals’s price movement after its last earnings report?
Fusion Pharmaceuticals reported an EPS of -$0.4 in its last earnings report, missing expectations of -$0.371. Following the earnings report the stock price went down -0.093%.
Which hedge fund is a major shareholder of Fusion Pharmaceuticals?
Among the largest hedge funds holding Fusion Pharmaceuticals’s share is Deerfield Management Company, LP. It holds Fusion Pharmaceuticals’s shares valued at 62M.
---
Fusion Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$20.94 (-2.51% Downside)
$20.94 (-2.51% Downside)
Blogger Sentiment
Bullish
FUSN Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 3.7M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 4.8%
Last 30 Days ▼ 4.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
380.53%
12-Months-Change
Fundamentals
Return on Equity
-47.11%
Trailing 12-Months
Asset Growth
21.48%
Trailing 12-Months
Company Description
Fusion Pharmaceuticals
Fusion Pharmaceuticals Inc is a clinical stage bio-pharmaceutical company focused on developing alpha therapeutics for curing cancer.
---
FUSN Stock 12 Month Forecast
Average Price Target
$20.94
▼(-2.51% Downside)
Best Analysts Covering FUSN
1 Year
1 Year Success Rate
4/4 ratings generated profit
1 Year Average Return
+281.07%
reiterated a buy rating 2 months ago
Copying Jeff Jones's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +281.07% per trade.
---